Horizon Pharma secures preliminary patent approval for urea disorder drug
Perspectivas América Latina 2023 Emerging Trends & Growth
Insight Weekly: SVB fallout limited; US rents up; renewable natural gas investments flow in
A Cloud Migration Plan for Corporations featuring Snowflake®
Investor Activism Campaigns Hit Record High in 2022
Horizon Pharma PLC secured preliminary approval for a U.S. patent that would cover its Ravicti oral treatment for urea cycle disorders in patients older than two years of age.
The U.S. Patent and Trademark Office issued a notice of allowance for the patent that would expire on Sept. 22, 2030, once granted.
